Internationally ranked for research impact, talent attraction and start-up generation.
Independent investment firm driving growth, private capital and cross-border deals—with deep roots in Asia and a long-term client focus.
Founded in 2016 as a spin-off of the Universitat Autònoma de Barcelona (UAB), BioEclosion designs portable diagnostics that deliver laboratory-quality answers where mains electricity, cold chain and specialised staff are unavailable. Working from the Eureka building on the UAB campus, the company couples magneto-electrochemical cartridges with a palm-size, battery-powered reader to obtain quantitative results in minutes. Each single-use cartridge houses freeze-dried reagents, magnetic micro-particles and a screen-printed electrode. After a sample is added, an internal magnet concentrates the particles on the electrode and the reader converts the electrochemical signal into a numeric result displayed on a smartphone or tablet. Protein or viral targets are measured in fifteen minutes, while on-cartridge isothermal amplification (AmpliFast) extends the platform to DNA or RNA in about thirty. Because only the cartridge changes, the same reader can be redeployed across human, veterinary, food-safety and environmental assays, providing a truly agnostic solution for emerging threats.
Four flagship programmes showcase this versatility. CeliFast replaces intestinal biopsy with a finger-stick blood test for coeliac disease. AmpliSenS / AmpliFast screens pregnant women and neonates for group B streptococcal sepsis at the point of care. AviaSenS detects avian influenza, Newcastle disease and infectious bronchitis virus directly on poultry farms, enabling same-day biosecurity action. EChiLiBRiST, a €6.5 million Horizon Europe consortium, validates a multiplex cartridge that stratifies paediatric fever severity across three African countries to improve triage and antibiotic stewardship. The company is led by co-founder and Chief Executive Officer Dr Jofre Ferrer-Dalmau, a GLP-trained PhD in Biomedicine, and co-founder Prof María I. Pividori, a tenure-track electrochemical-sensor specialist with more than 120 peer-reviewed publications and an h-index of 32. Six international patent families shield BioEclosion’s core technology, while strategic support from Addenda Capital, European research grants and the UAB innovation ecosystem fuels its growth. Anchored in rigorous science and user-centred design, BioEclosion’s goal is clear: make high-precision diagnostics fast, affordable and accessible to anyone, anywhere.
OUR TEAM
Product Advisor
Scientific Advisor
Medical Advisor
Veterinarian Advisor
Internationally ranked for research impact, talent attraction and start-up generation.
Independent investment firm driving growth, private capital and cross-border deals—with deep roots in Asia and a long-term client focus.
Input your search keywords and press Enter.
